Imugene Limited

OTCPK:IUGN.F Stock Report

Market Cap: US$180.2m

Imugene Valuation

Is IUGN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IUGN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IUGN.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IUGN.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IUGN.F?

Key metric: As IUGN.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IUGN.F. This is calculated by dividing IUGN.F's market cap by their current book value.
What is IUGN.F's PB Ratio?
PB Ratio2.4x
BookAU$118.25m
Market CapAU$283.38m

Price to Book Ratio vs Peers

How does IUGN.F's PB Ratio compare to its peers?

The above table shows the PB ratio for IUGN.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.8x
PLX Protalix BioTherapeutics
5.4x123.8%US$176.0m
NVCT Nuvectis Pharma
16.5x45.2%US$181.4m
INBX Inhibrx Biosciences
1x-135.7%US$181.8m
CRGX CARGO Therapeutics
0.4x12.9%US$173.5m
IUGN.F Imugene
2.4x22.6%US$283.4m

Price-To-Book vs Peers: IUGN.F is good value based on its Price-To-Book Ratio (2.4x) compared to the peer average (5.8x).

Price to Book Ratio vs Industry

How does IUGN.F's PB Ratio compare vs other companies in the US Biotechs Industry?

72 CompaniesPrice / BookEstimated GrowthMarket Cap
FDMT 4D Molecular Therapeutics
0.4x-4.7%US$214.50m
LYEL Lyell Immunopharma
0.4x-13.7%US$204.72m
NKTX Nkarta
0.3x-9.5%US$144.67m
KYTX Kyverna Therapeutics
0.4x-19.7%US$120.02m
IUGN.F 2.4xIndustry Avg. 1.7xNo. of Companies76PB01.63.24.86.48+
72 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IUGN.F is expensive based on its Price-To-Book Ratio (2.4x) compared to the US Biotechs industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is IUGN.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IUGN.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IUGN.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IUGN.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.029
US$0.15
+428.4%
63.0%US$0.28US$0.063n/a3
Feb ’26US$0.025
US$0.16
+543.3%
67.0%US$0.31US$0.062n/a3
Jan ’26US$0.021
US$0.16
+629.3%
67.0%US$0.30US$0.062n/a3
Dec ’25US$0.024
US$0.20
+714.0%
55.5%US$0.33US$0.067n/a4
Nov ’25US$0.031
US$0.20
+547.5%
55.5%US$0.33US$0.068n/a4
Oct ’25US$0.036
US$0.20
+464.5%
55.5%US$0.33US$0.068n/a4
Sep ’25US$0.039
US$0.23
+490.7%
41.5%US$0.32US$0.098n/a3
Aug ’25US$0.036
US$0.23
+524.3%
41.5%US$0.32US$0.097n/a3
Jul ’25US$0.041
US$0.23
+455.8%
41.5%US$0.32US$0.097n/a3
Jun ’25US$0.046
US$0.23
+395.4%
41.5%US$0.32US$0.097n/a3
May ’25US$0.052
US$0.23
+334.1%
41.5%US$0.32US$0.097n/a3
Apr ’25US$0.07
US$0.22
+215.3%
50.4%US$0.32US$0.066n/a3
Mar ’25US$0.075
US$0.23
+205.7%
50.6%US$0.32US$0.066n/a3
Feb ’25US$0.068
US$0.23
+237.1%
50.6%US$0.32US$0.066US$0.0253
Jan ’25US$0.06
US$0.23
+282.6%
50.6%US$0.32US$0.066US$0.0213
Dec ’24US$0.069
US$0.23
+235.6%
50.6%US$0.33US$0.066US$0.0243
Nov ’24US$0.028
US$0.23
+734.8%
52.2%US$0.34US$0.063US$0.0313
Oct ’24US$0.034
US$0.27
+694.5%
35.5%US$0.35US$0.14US$0.0363
Sep ’24US$0.042
US$0.31
+647.0%
36.7%US$0.45US$0.13US$0.0394
Aug ’24US$0.08
US$0.31
+293.2%
37.8%US$0.47US$0.14US$0.0364
Jul ’24US$0.059
US$0.31
+425.4%
37.8%US$0.47US$0.14US$0.0414
Jun ’24US$0.068
US$0.31
+358.4%
37.8%US$0.47US$0.14US$0.0464
May ’24US$0.09
US$0.34
+282.3%
25.8%US$0.48US$0.24US$0.0524
Apr ’24US$0.09
US$0.34
+282.1%
25.8%US$0.48US$0.24US$0.074
Mar ’24US$0.091
US$0.34
+276.0%
25.8%US$0.48US$0.24US$0.0754
Feb ’24US$0.10
US$0.34
+239.0%
25.8%US$0.48US$0.24US$0.0684
Analyst Price Target
Consensus Narrative from 3 Analysts
US$0.18
Fair Value
84.2% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/23 05:26
End of Day Share Price 2025/02/21 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imugene Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Dennis HulmeEdison Investment Research